Abstract
Several cancer drugs intercept the ErbB family receptors EGFR (ErbB-1) and HER2 (ErbB-2). However, the therapeutic value of targeting ErbB-3 has been less clear. A report in this issue of Cancer Cell by Sheng et al. renews hopes that intercepting ErbB-3-mediated autocrine loops bears potential for treatment of ovarian cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 217-218 |
Number of pages | 2 |
Journal | Cancer Cell |
Volume | 17 |
Issue number | 3 |
DOIs | |
State | Published - Mar 16 2010 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research